Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 18, 2019

Aerpio completes dosing in TIME-2b study of AKB-9778

Aerpio Pharmaceuticals has completed patient dosing in the Phase II TIME-2b clinical trial evaluating the efficacy and safety of AKB-9778 for the treatment of patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).

Aerpio Pharmaceuticals has completed patient dosing in the Phase II TIME-2b clinical trial evaluating the efficacy and safety of AKB-9778 for the treatment of patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).

Diabetic retinopathy (DR) is a complication of diabetes that occurs due to damage in blood vessels in the retina. It is estimated to affect around one-third of patients with diabetes.

The double-masked, placebo-controlled TIME-2b study intends to enrol 167 patients.

Aerpio randomised patients to receive either 15mg of AKB-9778 plus placebo once daily, AKB-9778 15mg twice daily, or placebo twice daily for the period of 48 weeks. All doses were administered subcutaneously.

“We believe AKB-9778 has the potential to provide patients with diabetes a significant treatment option, spanning multiple diabetic complications.”

The multi-centre trial’s primary objective is the percentage of patients who show improvement of two or more steps as measured by diabetic retinopathy severity score (DRSS) in the study eye.

Its secondary objectives include the urine albumin to creatinine ratio (UACR), which is based on a post-hoc evaluating of UACR in the TIME-2 Phase IIa clinical trial of AKB-9778.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Initial results from the TIME-2b study are expected to be available in March this year.

Aerpio Pharmaceuticals CEO Stephen Hoffman said: “We now expect to announce top-line results in March 2019, earlier than our previous guidance of the second quarter of 2019.

“The data obtained in our TIME-2 Phase IIa study were very encouraging, not only in demonstrating improvement in diabetic retinopathy, but also showing, in a post-hoc analysis, improvement of kidney function.

“We believe AKB-9778 has the potential to provide patients with diabetes a significant treatment option, spanning multiple diabetic complications.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU